---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042390"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:10:48.266623+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx FDA partial clinical hold lifted for iMMagine-1; Q2 net loss $23.9M

## Summary
- FDA lifted partial clinical hold on CART-ddBCMA Phase 2 iMMagine-1 trial after patient death and protocol modifications.
- Cash, cash equivalents, and marketable securities $506.5M; funds operations through BLA filing into 2026.
- Collaboration revenue of $14.3M from Kite partnership; R&D expenses $28.3M, G&A $15.5M.
- Net loss improved to $23.9M vs $30.8M in Q2 2022; preliminary iMMagine-1 data expected 2H 2024.
- Expanded bridging therapies allowed under revised protocol; all 17 previously enrolled patients dosed during hold.

## SEC filing metadata
- accession: 0000950170-23-042390
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/0000950170-23-042390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/aclx-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042390
- JSON: https://secwatch.observer/filing/0000950170-23-042390.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042390.txt

## Key facts
- Earnings Releases
  Arcellx, Inc. reported second quarter ended June 30, 2023 results: revenue $14.3 million, net income $23.9 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $14.3 million
  - Net income: $23.9 million
  - Result: reported results
  source text: Collaboration revenue was $14.3 million and $0 for the quarters ended June 30, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/0000950170-23-042390-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.